• Niagen Bioscience's third-quarter 2026 earnings call featured CEO Robert N. Fried and CFO Ozan Pamir.
• Net sales totaled USD 27.2 million; net loss reached USD 1.2 million, or USD 0.01 per diluted share.
• Management expects fourth-quarter revenue to improve sequentially, with higher marketing spending supporting brand campaigns, distribution and new products.
• NB4168's IND-enabling studies are targeted for completion in early 2027, with first-in-human testing planned that year, subject to regulatory clearance.
• Commercialization of lower-cost NR malate is expected in early 2027, reducing ingredient costs initially, with more significant savings anticipated thereafter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.